ArticlePLoS neglected tropical diseases2025
Unveiling immunity dynamics: Serological characteristics of antibodies against Japanese encephalitis virus in Guangdong, China.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundDefining the immune dynamics of Japanese encephalitis (JE) in healthy individuals is crucial for assessing population susceptibility and evaluating the effectiveness of vaccinations.
methodsWe conducted a cross-sectional serological survey of anti-JEV IgG antibodies and anti-JEV neutralizing antibodies (nAbs) in Guangzhou City, Zhanjiang City and Heyuan City of Guangdong Province, China.
resultsA total of 691 participants were included from 2018-2022, among whom 50 were dengue IgG antibody positive and 641 were dengue IgG antibody negative. In the total population, the anti-JEV IgG antibody positivity rate detected by enzyme-linked immunosorbent assay (ELISA) was 51.37% (95% CI: 47.64-55.11%), and the neutralizing antibody positivity rate detected using the microneutralization test (MNT) was 73.22% (95% CI: 69.92-76.54%). Among the 641 dengue IgG antibody-negative subjects, the anti-JEV IgG antibody positivity rate by ELISA and the neutralizing antibody positivity rate by MNT were 48.05% (95% CI: 44.17-51.93%) and 72.07% (95% CI: 68.59-74.56%), respectively. Comparable geographical seroprevalences of either anti-JEV IgG or neutralizing antibody were observed in Guangzhou City, Heyuan City and Zhanjiang City, respectively (49.52% vs. 48.04% vs. 47.45%, 65.71% vs. 70.46% vs. 76.47%, respectively). Antibody positivity rates in all age groups exhibited a U-shaped curve, with the lowest rate occurring in the 7-18-year-old age group. With respect to the vaccine dose, the anti-JEV nAb positivity rate and geometric mean titer (GMT) detected by MNT were higher in those who received two doses of live attenuated vaccine than in those who received one dose or 0 doses (80.57% vs. 55.81% vs. 55.09% and 25.92 vs. 12.19 vs. 16.47, respectively). In the 641 dengue IgG antibody-negative subjects, moderate consistency between the MNT and ELISA results was observed (Kappa = 0.47, rs = 0.76).
conclusionThe high seroprevalence in participants indicated a neglected transmission of JE, which highlights the importance of strengthening the surveillance of JEV in this area. The vaccination program against JEV is highly needed because of immune gaps in adults, e.g., boosters for adults aged 7-39 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.